Tsingke Biotech

What Tsingke Biotech does

Beijing Tsingke Biotech Co., Ltd. is a privately held Chinese biotechnology company founded in 2017 that operates an integrated DNA and RNA synthesis services platform branded as the 'Gene Factory'. The company produces phosphoramidites, enzymes, and buffers in-house and operates self-developed synthesis instruments ranging from 12-channel to 768-channel configurations, enabling an integrated workflow from raw reagents through GMP-grade oligonucleotide, gene, protein, antibody, and viral vector deliverables. Sub-brands Tsynth, Tsecure, ProLong, and Gene Factory segment the offering across standard gene synthesis, secure/IP-protected synthesis, extended-length synthesis, and the broader platform.

Tsingke serves over 300,000 cumulative customers spanning academic researchers, research institutes, biotech startups, and biopharmaceutical companies, with disclosed logos concentrated in global universities (University of Virginia, Aarhus, Macquarie, Florida, Eindhoven, Queensland, Groningen, KAUST, Helsinki, Málaga), cancer research centers (VIB-KU Leuven), and life sciences distributors (Avantor). The platform addresses use cases in antibody drug discovery, molecular diagnostics, vaccine development, gene editing, gene therapy, and agricultural biotech through application-specific landing pages and standardized service packages.

The business model is B2B project-based services revenue, quote-driven with no public list pricing, supported by a sales-led go-to-market combining direct sales (with representatives in Beijing Yizhuang and Tianjin), digital self-service quote requests, and industry conference presence (TIDES USA, AACR, BIO-Europe, Festival of Biologics). The company has raised approximately $88.9 million across two 2022 rounds and operates from a 70,000 m² footprint with GMP-compliant facilities in Beijing and Suzhou.

Name

Tsingke Biotech

Legal name

Beijing Tsingke Biotech Co., Ltd.

Website

https://tsingke.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Tsingke Biotech is a Beijing-based, privately held DNA and RNA synthesis services company operating an integrated 'Gene Factory' platform that delivers custom genes, oligos, proteins, antibodies, and viral vectors to over 300,000 research institutions and biopharmaceutical customers globally.

Ownership category

akta.pro rank

Product category

DNA/RNA Synthesis Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industries

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)

Keywords

• DNA synthesis services
• RNA synthesis services
• Gene synthesis
• Oligonucleotide synthesis
• Viral vector packaging

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Gene Synthesis Services: Custom gene synthesis from fragments to full-length genes with codon optimization, cloning, and expression-ready formatting. Revenue generated through project-based pricing per synthesis request.
2. Oligo Synthesis Services: Custom DNA and RNA oligonucleotide synthesis with flexible scales, modifications, and QC options for qPCR, cloning, sequencing, gene editing, and diagnostic applications.
3. Protein & Antibody Services: Custom protein expression, purification, and antibody production using E. coli, mammalian, or baculovirus systems with quality analytics and scalability.
4. Viral Vector Packaging: Plasmid prep, lentiviral packaging, AAV production, and LNP-formulated RNA services tailored for gene therapy, vaccine R&D, and in vitro functional studies.
5. Gene Delivery Services: Gene delivery solutions including virus packaging for AAV, LV, and AdV formats.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Tsingke Biotech operates an integrated "Gene Factory" platform that delivers custom DNA and RNA synthesis services, including oligonucleotides, gene synthesis, protein expression, antibody services, and viral vector packaging. The company combines in-house reagent production (phosphoramidites, enzymes, buffers) with proprietary 12 to 768-channel synthesis instruments and automated workflows to serve research institutions and biopharmaceutical companies worldwide with scale ranging from 2nmol laboratory grade to 12mmol industrial GMP-grade production.

Differentiator

Problem solved

Functional benefit

Brands

• Tsynth: Gene synthesis service brand
• Tsecure
• ProLong
• Gene Factory

Products and services

• Custom Oligonucleotide Synthesis
• Gene Synthesis (Tsynth)
• Gene Cloning Services
• saRNA and circRNA Synthesis
• IVT mRNA Synthesis
• Protein Expression and Purification Services
• Antibody Discovery and Production Services
• Viral Vector Packaging Services
• Zero-Contact Sequences System
• Next-Generation Rapid Protein and Antibody Solutions

Quantifiable outcome

• Protein generation within 3 days
• +3 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• iGeneTech Bioscience Co., Ltd.coreStrategic or Co-development Partner · 10 March 2026Strategic partnership combining Tsingke's gene synthesis capabilities and integrated industrial chain (from 2nmol laboratory scale to 12mmol industrial scale) with iGeneTech's Ignite 3.0 high-throughput synthesis platform processing oligo pools from 4k to 650k in size with error rates as low as 0.2%. The collaboration targets precision medicine, bio-breeding, and gene editing markets with the goal of developing an integrated system spanning from synthesis to application.
• Zhejiang UniversitycoreStrategic or Co-development Partner · 20 January 2025Joint laboratory collaboration agreement to advance small nucleic acid drug delivery research. Combines Tsingke's synthesis capabilities with Zhejiang University's academic research expertise.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GenScript: GenScript is a global biotech offering gene synthesis, oligo synthesis, protein/antibody services, and viral vector packaging—the same end-to-end CDMO model as Tsingke's Gene Factory. It is the closest head-to-head competitor across nearly every revenue stream Tsingke operates in.
• Twist Bioscience: Twist Bioscience is a US-based DNA synthesis leader using silicon-platform writing technology, with overlapping oligo synthesis, gene synthesis, and DNA data storage offerings. It is a direct competitor in synthetic DNA manufacturing and NGS oligo pools, where Tsingke's iGeneTech partnership (Ignite 3.0) explicitly competes.
• Integrated DNA Technologies (IDT): IDT, owned by Danaher, is a market leader in custom DNA/RNA oligo synthesis, modifications, and qPCR/NGS reagents. It directly competes with Tsingke's core oligo synthesis and IVD-grade probes/primers businesses across academic and diagnostic customers globally.
• Synbio Technologies: Synbio Technologies is a gene synthesis and synthetic biology CDMO offering gene synthesis, oligo pools, and protein services. It is a direct comparable in the synthetic biology services market, particularly competing in Asia-Pacific and global academic accounts.
• Bioneer: Bioneer is a Korean biotech offering custom oligo synthesis, gene synthesis, and molecular diagnostics reagents. It directly competes with Tsingke in custom DNA/RNA synthesis and IVD probe/primer manufacturing, particularly in APAC.
• ATUM (formerly DNA2.0): ATUM is a synthetic biology company offering gene synthesis, protein engineering, and antibody discovery services. It overlaps with Tsingke's gene synthesis, protein expression, and antibody discovery offerings, particularly for early-stage biotech and academic customers.
• iGeneTech Bioscience: iGeneTech is a Chinese NGS oligo pool and target capture probe provider, partner of Tsingke via the Ignite 3.0 integration. It is a direct comparable in high-throughput oligo pool synthesis and a strategic partner/co-competitor in NGS oligos and target enrichment.

Broad incumbents

• Eurofins Genomics: Eurofins Genomics is the genomics services arm of Eurofins Scientific, offering oligo synthesis, gene synthesis, sequencing, and genotyping at large scale. It is a broad incumbent with overlapping capabilities but serves a wider portfolio including sequencing and routine genomics testing.
• Thermo Fisher Scientific: Thermo Fisher provides oligo synthesis (via Invitrogen), gene synthesis services, and a broad life sciences portfolio. It is a broad incumbent competing on scale, catalog offerings, and bundled procurement contracts rather than Tsingke's custom CDMO model.

Emerging players

• Bio Basic: Bio Basic is a Canadian-China based provider of custom oligo synthesis, gene synthesis, and peptide services. It is an emerging player with overlapping offerings, competing primarily on price in commodity oligo and gene synthesis markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/TsingkeBio
• LinkedInlinkedin.com/company/tsingke

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tsingke Biotech